Indian stocks: Visit www.stage2stocks.com →

Oruka Therapeutics, Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, Oruka Therapeutics is in Stage 3, the topping phase, now in week 2 (since Oct 9, 2026). It closed at $81.15, 28.2% below its 52-week high and above its 200-day average, which is rising.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. More about the company

$81.15
+1.54% today
$5.4B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is ORKA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 32w
S2 15w
S4 22w
S2 58w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 32w → S1 2w → S2 15w → S3 5w → S2 12w → S3 6w → S4 22w → S1 11w → S2 58w → S3 2w current
Total tracked: 165 weeks across 10 stage runs.

ORKA among Biotechnology10th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…10ORKAStage 3 · wk 298−9.8%
vs 52W High
-28.2%
$26.19 lo$113.08 hi
28.2% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 2
1w13w26w
Week 2, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
20.5%
200 DMA: $67.33 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.64x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-9.8%
3M
-11.9%
6M
+19.8%
YTD
+187.1%
1Y
+196.6%
Scan Membership
Breakout Watch
Latest: 2024-09-03
6 appearances in last 60 days. First seen: 2018-11-29.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 2 · Vol 0.64x
2026-10-21S3
Wk 2 · Vol 1.03x
2026-10-20S3
Wk 2 · Vol 0.86x
2026-10-19S3
Wk 2 · Vol 0.89x
2026-10-16S3
Wk 2 · Vol 1.55x
2026-10-15S3
Wk 1 · Vol 1.38x
2026-10-14S3
Wk 1 · Vol 0.78x
2026-10-13S3
Wk 1 · Vol 0.57x
2026-10-12S3
Wk 1 · Vol 0.61x
2026-10-09S32→3
Wk 1 · Vol 1.34x
2026-10-08S2
Wk 56 · Vol 1.38x
2026-10-07S2
Wk 56 · Vol 0.91x
Moving averages & range
50 DMA
$90.55
200 DMA
$67.33
52W High
$113.08
52W Low
$26.19
5D Low
$71.93
Resistance levels (recent highs)
20d High
$84.52
60d High
$113.08
120d High
$113.08
250d High
$113.08
Next resistance
+4.2%
to 20d High
ROE
-18.2%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 4.5

Oruka Therapeutics: quick answers

What stage is Oruka Therapeutics in?

As of Oct 22, 2026, Oruka Therapeutics (ORKA) is in Stage 3, the topping phase. It entered Stage 3 on Oct 9, 2026 and is in week 2. What the four stages mean

Is Oruka Therapeutics in an uptrend?

Its uptrend has stalled. Oruka Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 20.5% above its 200-day average, which is rising.

How far is Oruka Therapeutics from its 52-week high?

Oruka Therapeutics closed at $81.15 on Oct 22, 2026, 28.2% below its 52-week high of $113.08. Its 52-week low is $26.19.

How has Oruka Therapeutics performed over the past year?

As of Oct 22, 2026, Oruka Therapeutics is up 196.6% over the past year and up 187.1% so far in 2026.

Which sector and industry is Oruka Therapeutics in?

Oruka Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.